However, guidelines from Kidney Disease Improving Global Outcomes (KDIGO) recommend that active vitamin D or analogues for secondary hyperparathyroidism treatment should be introduced only in late stages of CKD and end-stage renal disease in dialysis, and that their use should be reserved for patients with uncontrolled or rapidly increasing parathyroid hormone levels [26]. The gene discussed is PTH; the disease is kidney disorder.